FDMT تصريحات هيئة الأوراق المالية والبورصات - 4D Molecular Therapeutics, Inc.- التقرير السنوي، بيان التوكيل، نشرة الإصدار

الإحصائيات الأساسية

CIK

1650648

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to 4D Molecular Therapeutics, Inc.

SEC Filings (Chronological Order)

توفر هذه الصفحة قائمة كاملة ومرتبة ترتيبًا زمنيًا لتصريحات هيئة الأوراق المالية والبورصات، باستثناء تصريحات الملكية التي نقدمها في مكان آخر.

August 11, 2025	8-K	FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2025 4D Molecular Therapeutics Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39782 47-3506994 (State or Other Jurisdiction of Incorporation) (Com
August 11, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39782 4D Molecula
August 11, 2025	EX-99.1	4DMT Reports Second Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones Exhibit 99.1 4DMT Reports Second Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones • 4D-150 Phase 3 program in wet AMD advancing ahead of plan, with expected 4FRONT-1 data readout accelerated to H1 2027 from H2 2027 and 4FRONT-2 initiated ahead of schedule • Presented positive 60-week results from 4D-150 SPECTRA clinical trial in DME • Streamlined organization
July 2, 2025	8-K	FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 27, 2025 4D Molecular Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39782 47-3506994 (State or Other Jurisdiction of Incorporation) (Comm
June 20, 2025	8-K	FORM 8-K Item 5.07 Submission of Matters to a Vote of Security Holders. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17, 2025 4D Molecular Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39782 47-3506994 (State or Other Jurisdiction of Incorporation) (Comm
May 8, 2025	EX-99.1	4DMT Reports First Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones Exhibit 99.1 4DMT Reports First Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones • Enrolled first patients in first 4D-150 Phase 3 clinical trial (4FRONT-1) in wet AMD, with over 50 clinical trial sites open to date • Initiation of second 4D-150 Phase 3 clinical trial (4FRONT-2) expected in Q3 2025, with topline data from both 4FRONT-1 and 4FRONT-2 expected i
May 8, 2025	EX-FILING FEES	Calculation of Filing Fee Table. Calculation of Filing Fee Tables S-8 4D Molecular Therapeutics, Inc. Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity Common stock, $0.0001 par value per share Other 307,939 $ 2.68 $ 825,276.52 0.0001531 $ 126.35 Total
May 8, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39782 4D Molecul
May 8, 2025	8-K	FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 08, 2025 4D Molecular Therapeutics Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39782 47-3506994 (State or Other Jurisdiction of Incorporation) (Commis
May 8, 2025	S-8	Power of Attorney (included in the signature page to this registration statement). S-8 As filed with the Securities and Exchange Commission on May 8, 2025 Registration No.
April 29, 2025	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy S
April 29, 2025	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ D
February 28, 2025	EX-10.20	Form of Restricted Stock Unit Award Grant Notice and Restricted Stock Unit Award Agreement under the 2025 Employment Inducement Award Plan. Exhibit 10.20 4D MOLECULAR THERAPEUTICS, INC. 2025 EMPLOYMENT INDUCEMENT AWARD PLAN RESTRICTED STOCK UNIT AWARD GRANT NOTICE 4D Molecular Therapeutics, Inc., a Delaware corporation (the “Company”), pursuant to its 2025 Employment Inducement Award Plan, as amended from time to time (the “Plan”), hereby grants to the holder listed below (the “Participant”), an award of restricted stock units (“Restr
February 28, 2025	EX-10.19	2025 Employment Inducement Award Plan. Exhibit 10.19 4D Molecular Therapeutics, Inc. 2025 EMPLOYMENT INDUCEMENT AWARD PLAN ARTICLE I. Purpose The Plan’s purpose is to enhance the Company’s ability to attract, retain and motivate employees who are expected to make important contributions to the Company by providing these individuals with equity ownership opportunities. ARTICLE II. Definitions As used in the Plan, the following words and
February 28, 2025	EX-10.21	Form of Stock Option Grant Notice and Stock Option Agreement under the 2025 Employment Inducement Award Plan. Exhibit 10.21 4D MOLECULAR THERAPEUTICS, INC. 2025 EMPLOYMENT INDUCEMENT AWARD PLAN STOCK OPTION GRANT NOTICE 4D Molecular Therapeutics, Inc., a Delaware corporation (the “Company”), pursuant to its 2025 Employment Inducement Award Plan, as may be amended from time to time (the “Plan”), hereby grants to the holder listed below (“Participant”), an option to purchase the number of shares of the Comp
February 28, 2025	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39782 4D Molecular Th
February 28, 2025	EX-FILING FEES	Filing Fee Table. Exhibit 107.1 Calculation of Filing Fee Tables Form S-3 (Form Type) 4D Molecular Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Regist
February 28, 2025	EX-99.1	4DMT Reports Full Year 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones Exhibit 99.1 4DMT Reports Full Year 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones • Presented positive interim data through 52 weeks and beyond for 4D-150 in wet AMD from PRISM Phase 1/2 clinical trial highlighting robust and durable clinical activity across diverse patient populations and continued favorable tolerability • Announced positive interim 32-week data
February 28, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2025 4D Molecular Therapeutics Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39782 47-3506994 (State or Other Jurisdiction of Incorporation) (C
February 28, 2025	EX-19.1	Insider Trading Compliance Policy, dated as of November 4, 2024 Certain confidential information contained in this document, marked by brackets and asterisks, has been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K, because the Company treats such information as private or confidential and the omitted information is not material.
February 28, 2025	S-8	As filed with the Securities and Exchange Commission on February 28, 2025 S-8 As filed with the Securities and Exchange Commission on February 28, 2025 Registration No.
February 28, 2025	EX-4.1	Description of Securities of the Registrant. Exhibit 4.1 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of December 31, 2024, 4D Molecular Therapeutics, Inc. had one class of common stock registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). The following summary describes our capital stock and the material provisions of our
February 28, 2025	POS AM	Powers of Attorney (incorporated by reference to the signature page hereto). Table of Contents As filed with the Securities and Exchange Commission on February 28, 2025 Registration No.
February 28, 2025	POSASR	As filed with the Securities and Exchange Commission on February 28, 2025 Table of Contents As filed with the Securities and Exchange Commission on February 28, 2025 Registration No.
February 28, 2025	EX-FILING FEES	Calculation of Filing Fee Table. Exhibit 107.1 Calculation of Filing Fee Tables Form S-8 (Form Type) 4D Molecular Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1—Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount to be Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common s
February 14, 2025	EX-99.1	JOINT FILING AGREEMENT EX-99.1 2 ex-99-02142025110212.htm JOINT FILING AGREEMENT EXHIBIT 99.1 JOINT FILING AGREEMENT This Joint Filing Agreement, dated as of February 14, 2025, is by and among RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. (the foregoing are collectively referred to herein as the “Filers”). Each of the Filers may be required to file with the United State
February 14, 2025	EX-99.1	JOINT FILING AGREEMENT EX-99.1 2 ex-99-02142025110233.htm JOINT FILING AGREEMENT EXHIBIT 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the Common Stock of 4D Molecular Therapeutics, Inc. and further agree th
February 10, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 08, 2025 4D Molecular Therapeutics Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39782 47-3506994 (State or Other Jurisdiction of Incorporation) (C
February 10, 2025	EX-99	EX-99 EX-99 2 POA13G-2468332120250128.txt EXHIBIT 99 POWER OF ATTORNEY KNOW ALL PERSONS BY THESE PRESENTS that THE GOLDMAN SACHS GROUP, INC. (the "Company") does hereby make, constitute and appoint Papa Lette, Akash Keshari, Regina Chan, Andrzej Szyszka, Ameen Soetan, Rahail Patel, Santosh Vinayagamoorthy, Sadhiya Raffique, Matthew Pomfret, Abhishek Vishwanathan, Mariana Audeves, Veronica Mupazviriwo, E
January 10, 2025	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2025 4D Molecular Therapeutics Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39782 47-3506994 (State or Other Jurisdiction of Incorporation) (Co
January 10, 2025	EX-99.1	Legal Disclaimer This Presentation contains forward looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this Presentation, including statements regarding our cli Intravitreal 4D-150 DME Clinical Trial: Part 1 Interim 32-week Results January 10, 2025 EXHIBIT 99.
December 11, 2024	EX-4.1	Form of Pre-Funded Warrant issued in conjunction with December 2024 exchange. Exhibit 4.1 4D MOLECULAR THERAPEUTICS, INC. [FORM OF] WARRANT TO PURCHASE SHARES OF COMMON STOCK Number of Shares: 535,000 (subject to adjustment) Warrant No. CS - 8 Original Issue Date: December [ ], 2024 4D Molecular Therapeutics, Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged,
December 11, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 06, 2024 4D Molecular Therapeutics Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39782 47-3506994 (State or Other Jurisdiction of Incorporation) (C
November 15, 2024	EX-99.1	Exhibit 1: Joint Filing Agreement EX-99.1 2 tm2428635d1ex1.htm EXHIBIT 1 EXHIBIT 1 AGREEMENT This Joint Filing Agreement, dated as of November 15, 2024, is by and among RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. (the foregoing are collectively referred to herein as the “Filers”). Each of the Filers may be required to file with the United States Securities and Exchange Commissio
November 15, 2024	SC 13G/A	FDMT / 4D Molecular Therapeutics, Inc. / RA CAPITAL MANAGEMENT, L.P. - SC 13G/A Passive Investment SC 13G/A 1 tm2428635d1sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* 4D MOLECULAR THERAPEUTICS, INC. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 35104E100 (CUSIP Number) November 13, 2024 (Date of Event Which Requires Filing of this
November 14, 2024	SC 13G/A	FDMT / 4D Molecular Therapeutics, Inc. / RA CAPITAL MANAGEMENT, L.P. - SC 13G/A Passive Investment SC 13G/A 1 tm2427451d5sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* 4D MOLECULAR THERAPEUTICS, INC. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 35104E100 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this
November 14, 2024	EX-99.1	Exhibit 1: Joint Filing Agreement EX-99.1 2 tm2427451d5ex1.htm EXHIBIT 1 EXHIBIT 1 AGREEMENT This Joint Filing Agreement, dated as of November 14, 2024, is by and among RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. (the foregoing are collectively referred to herein as the “Filers”). Each of the Filers may be required to file with the United States Securities and Exchange Commissio
November 14, 2024	SC 13G/A	FDMT / 4D Molecular Therapeutics, Inc. / Deep Track Capital, LP Passive Investment SC 13G/A 1 deeptrack-fdmt093024a4.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 4)* 4D MOLECULAR THERAPEUTICS, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 35104E100 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this State
November 14, 2024	SC 13G/A	FDMT / 4D Molecular Therapeutics, Inc. / VIKING GLOBAL INVESTORS LP Passive Investment SC 13G/A 1 sayw2411142413ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS PURSUANT TO RULES 13d-1(b),(c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934* (Amendment No. 5) 4D Molecular Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Tit
November 13, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2024 4D Molecular Therapeutics Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39782 47-3506994 (State or Other Jurisdiction of Incorporation) (C
November 13, 2024	SC 13G/A	FDMT / 4D Molecular Therapeutics, Inc. / BIOTECHNOLOGY VALUE FUND L P - AMENDMENT NO. 3 TO SCHEDULE 13G Passive Investment SC 13G/A 1 sc13ga307422fdmt11142024.htm AMENDMENT NO. 3 TO SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 3)1 4D Molecular Therapeutics, Inc. (Name of Issuer) Common Stock, par
November 13, 2024	EX-99.1	4DMT Reports Third Quarter 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones Exhibit 99.1 4DMT Reports Third Quarter 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones • Presented positive interim data for 4D-150 in wet age-related macular degeneration (wet AMD) from PRISM Phase 1/2 clinical trial highlighting robust and durable clinical activity across diverse patient populations and intraocular inflammation (IOI) profile numerically similar t
November 13, 2024	EX-4.4	Form of Pre-Funded Warrant issued in conjunction with November 2024 exchange. Exhibit 4.4 4D MOLECULAR THERAPEUTICS, INC. [FORM OF] WARRANT TO PURCHASE SHARES OF COMMON STOCK Number of Shares: [ ] (subject to adjustment) Warrant No. CS - [ ] Original Issue Date: October [ ], 2024 4D Molecular Therapeutics, Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [
November 13, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39782 4D Mol
November 8, 2024	SC 13G/A	FDMT / 4D Molecular Therapeutics, Inc. / BlackRock, Inc. Passive Investment SC 13G/A 1 us35104e1001110824.txt us35104e1001110824.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 3) 4D Molecular Therapeutics Inc. - (Name of Issuer) Common Stock - (Title of Class of Securities) 35104E100 - (CUSIP Number) September 30, 2024 - (Date of Event Which Requires Filing of this Statement) Check the ap
September 18, 2024	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 18, 2024 4D Molecular Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39782 47-3506994 (State or Other Jurisdiction of Incorporation)
August 8, 2024	EX-99.1	4DMT Reports Second Quarter 2024 Financial Results and Operational Highlights Exhibit 99.1 4DMT Reports Second Quarter 2024 Financial Results and Operational Highlights • Announced positive interim results from the Population Extension cohort of the Phase 2 PRISM clinical trial for 4D-150 in a broad wet age-related macular degeneration (wet AMD) population, which includes patients representative of the planned Phase 3 study population, affirming favorable safety profile and
August 8, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39782 4D Molecula
August 8, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 08, 2024 4D Molecular Therapeutics Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39782 47-3506994 (State or Other Jurisdiction of Incorporation) (Com
July 23, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 23, 2024 4D Molecular Therap UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 23, 2024 4D Molecular Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39782 47-3506994 (State or Other Jurisdiction of Incorporation) (Comm
July 17, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 17, 2024 4D MOLECULAR THERAP UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 17, 2024 4D MOLECULAR THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39782 47-3506994 (State or other jurisdiction of incorporation) (Comm
June 7, 2024	EX-1.1	Sales Agreement, dated June 7, 2024, by and between the Company and Leerink Partners LLC Exhibit 1.1 SALES AGREEMENT June 7, 2024 Leerink Partners LLC 1301 Avenue of the Americas, 12th Floor New York, New York 10019 Ladies and Gentlemen: 4D Molecular Therapeutics, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Leerink Partners LLC, as sales agent and/or principal (the “Agent”), shar
June 7, 2024	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 7, 2024 4D Molecular Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39782 47-3506994 (State or Other Jurisdiction of Incorporation) (Commi
June 7, 2024	424B5	Up to $250,000,000 Common Stock Table of Contents Filed pursuant to Rule 424(b)(5) Registration No. 333-276872 PROSPECTUS SUPPLEMENT (To Prospectus dated February 5, 2024) Up to $250,000,000 Common Stock We have entered into a sales agreement (sales agreement) with Leerink Partners LLC (Leerink Partners) dated June 7, 2024, relating to shares of our common stock offered by this prospectus supplement and the accompanying prospect
June 7, 2024	EX-FILING FEES	CALCULATION OF FILING FEE TABLE (Form Type) 4D Molecular Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Propos Exhibit 107.1 CALCULATION OF FILING FEE TABLE 424(b)(5) (Form Type) 4D Molecular Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Newly Registered Sec
May 24, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 21, 2024 4D Molecular Therape UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 21, 2024 4D Molecular Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39782 47-3506994 (State or Other Jurisdiction of Incorporation) (Commi
May 9, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 09, 2024 4D Molecular Therapeutics Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39782 47-3506994 (State or Other Jurisdiction of Incorporation) (Commis
May 9, 2024	EX-99.1	4DMT Reports First Quarter 2024 Financial Results and Operational Highlights Exhibit 99.1 4DMT Reports First Quarter 2024 Financial Results and Operational Highlights • Announced positive interim data from PRISM Phase 2 Dose Expansion cohort evaluating 4D-150 in wet AMD patients with severe disease activity and high treatment burden enabling advancement into Phase 3 expected by Q1 2025 • Interim 24-week landmark analysis from PRISM Phase 2 Population Extension cohort evalu
May 9, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39782 4D Molecul
April 10, 2024	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy S
April 10, 2024	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ D
February 29, 2024	EX-10.16	Change in Control and Severance Agreement, dated September 22, 2021, by and between Scott Bizily and the Registrant Exhibit 10.16 4D MOLECULAR THERAPEUTICS, INC. CHANGE IN CONTROL AND SEVERANCE AGREEMENT This Change in Control and Severance Agreement (the “Agreement”) is made and entered into by and between Scott Bizily (“Executive”) and 4D Molecular Therapeutics, Inc. (the “Company”), effective as of the latest date set forth by the signatures of the parties hereto below (the “Effective Date”). Background A. T
February 29, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 29, 2024 4D Molecular Therapeutics Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39782 47-3506994 (State or Other Jurisdiction of Incorporation) (C
February 29, 2024	EX-10.17	Amended and Restated Change in Control and Severance Agreement, dated June 23, 2023 by and between Robert Kim and the Registrant Exhibit 10.17 4D MOLECULAR THERAPEUTICS, INC. AMENDED AND RESTATED CHANGE IN CONTROL AND SEVERANCE AGREEMENT This Amended and Restated Change in Control and Severance Agreement (the “Agreement”) is made and entered into by and between Robert Young Kim (“Executive”) and 4D Molecular Therapeutics, Inc. (the “Company”), effective as of the latest date set forth by the signatures of the parties hereto
February 29, 2024	S-8	As filed with the Securities and Exchange Commission on February 29, 2024 As filed with the Securities and Exchange Commission on February 29, 2024 Registration No.
February 29, 2024	EX-97	Registrant’s Policy for Recovery of Erroneously Awarded Compensation Exhibit 97 4D MOLECULAR THERAPEUTICS, INC. POLICY FOR RECOVERY OF ERRONEOUSLY AWARDED COMPENSATION 4D Molecular Therapeutics, Inc. (the “Company”) has adopted this Policy for Recovery of Erroneously Awarded Compensation (the “Policy”), effective as of October 2, 2023 (the “Effective Date”). Capitalized terms used in this Policy but not otherwise defined herein are defined in Section 11 of this Pol
February 29, 2024	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39782 4D Molecular Th
February 29, 2024	EX-10.15	Change in Control and Severance Agreement, dated August 29, 2023, by and between Uneek Mehra and the Registrant Exhibit 10.15 4D MOLECULAR THERAPEUTICS, INC. CHANGE IN CONTROL AND SEVERANCE AGREEMENT This Change in Control and Severance Agreement (the “Agreement”) is made and entered into by and between (“Executive”) and 4D Molecular Therapeutics, Inc. (the “Company”), effective as of the latest date set forth by the signatures of the parties hereto below (the “Effective Date”). Background A. The Board of D
February 29, 2024	EX-FILING FEES	Calculation of Filing Fee Table Exhibit 107.1 Calculation of Filing Fee Tables Form S-8 (Form Type) 4D Molecular Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1—Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount to be Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common st
February 29, 2024	EX-99.1	4DMT Reports Full Year 2023 Financial Results and Operational Highlights Exhibit 99.1 4DMT Reports Full Year 2023 Financial Results and Operational Highlights • Presented positive interim data from randomized Dose Expansion cohort of the Phase 2 PRISM study evaluating 4D-150 in wet AMD patients with severe disease activity and high treatment burden, enabling advancement into Phase 3 pivotal development, with initiation expected in Q1 2025 • Positive interim clinical da
February 29, 2024	EX-10.14	Offer Letter, dated September 4, 2023, between Uneek Mehra and the Registrant Exhibit 10.14 September 4, 2023 Uneek Mehra 714 Jacaranda Circle Hillsborough, CA 94010 Dear Uneek: We are pleased to make you the following offer of employment. We believe you will play an important and meaningful role in our mission of developing transformative genetic medicines for our patients. Position and Location of Role. Your title will be Chief Financial and Business Officer, reporting to
February 14, 2024	SC 13G/A	FDMT / 4D Molecular Therapeutics, Inc. / Deep Track Capital, LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No.
February 14, 2024	EX-99.1	Exhibit 1: Joint Filing Agreement EX-99.1 2 tm246065d1ex1.htm EXHIBIT 1 EXHIBIT 1 AGREEMENT This Joint Filing Agreement, dated as of February 14, 2024, is by and among RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. (the foregoing are collectively referred to herein as the “Filers”). Each of the Filers may be required to file with the United States Securities and Exchange Commission
February 14, 2024	SC 13G/A	FDMT / 4D Molecular Therapeutics, Inc. / RA CAPITAL MANAGEMENT, L.P. - SC 13G/A Passive Investment SC 13G/A 1 tm246065d113ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* 4D MOLECULAR THERAPEUTICS, INC. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 35104E100 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Sta
February 14, 2024	SC 13G/A	FDMT / 4D Molecular Therapeutics, Inc. / Venrock Healthcare Capital Partners III, L.P. - SC 13G/A Passive Investment SC 13G/A 1 tm246235d11sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* 4D Molecular Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 35104E100 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this
February 14, 2024	SC 13G/A	FDMT / 4D Molecular Therapeutics, Inc. / Kirn David - SC 13G/A Passive Investment SC 13G/A 1 d780455dsc13ga.htm SC 13G/A United States Securities and Exchange Commission Washington, D.C. 20549 Schedule 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to § 240.13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 3)* 4D Molecular Therapeutics, Inc. (Name of Issuer) Common Stoc
February 14, 2024	SC 13G/A	FDMT / 4D Molecular Therapeutics, Inc. / BIOTECHNOLOGY VALUE FUND L P - AMENDMENT NO. 2 TO SCHEDULE 13G Passive Investment SC 13G/A 1 sc13ga207422fdmt02142024.htm AMENDMENT NO. 2 TO SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 2)1 4D Molecular Therapeutics, Inc. (Name of Issuer) Common Stock, par
February 9, 2024	EX-1.1	Underwriting Agreement, dated as of February 6, 2024, among 4D Molecular Therapeutics, Inc. and Goldman Sachs & Co. LLC, BofA Securities, Inc., Jefferies LLC and Barclays Capital Inc. Exhibit 1.1 4D Molecular Therapeutics, Inc. Common Stock, par value $0.0001 per share Pre-Funded Warrants to Purchase Shares of Common Stock Underwriting Agreement February 6, 2024 Goldman Sachs & Co. LLC BofA Securities, Inc. Jefferies LLC Barclays Capital Inc. As representatives (the “Representatives”) of the several Underwriters named in Schedule I hereto c/o Goldman Sachs & Co. LLC 200 West St
February 9, 2024	EX-4.1	Form of Pre-Funded Warrant issued in conjunction with February 2024 offering. Exhibit 4.1 4D MOLECULAR THERAPEUTICS, INC. [FORM OF] WARRANT TO PURCHASE SHARES OF COMMON STOCK Number of Shares: [ ] (subject to adjustment) Warrant No. CS - [ ] Original Issue Date: February [ ], 2024 4D Molecular Therapeutics, Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [
February 9, 2024	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 6, 2024 4D MOLECULAR THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39782 47-3506994 (State or other jurisdiction of incorporation) (C
February 8, 2024	424B5	6,586,015 Shares of Common Stock Pre-funded Warrants to Purchase 3,583,476 Shares of Common Stock Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-276872 PROSPECTUS SUPPLEMENT (To Prospectus dated February 5, 2024) 6,586,015 Shares of Common Stock Pre-funded Warrants to Purchase 3,583,476 Shares of Common Stock We are offering up to 6,586,015 shares of our common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase up to 3,583,476 shar
February 8, 2024	EX-FILING FEES	Calculation of Filing Fee Tables (Form Type) 4D Molecular Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Exhibit 107 Calculation of Filing Fee Tables 424(b)(5) (Form Type) 4D Molecular Therapeutics, Inc.
February 7, 2024	FWP	Common Stock Pre-funded Warrants to Purchase Shares of Common Stock Issuer Free Writing Prospectus Filed Pursuant to Rule 433 Dated February 6, 2024 Relating to Preliminary Prospectus Supplement Dated February 5, 2024 Registration Statement No.
February 5, 2024	EX-FILING FEES	Filing Fee Table. Exhibit 107.1 CALCULATION OF FILING FEE TABLE S-3ASR (Form Type) 4D Molecular Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Newly Re
February 5, 2024	424B5	Subject to Completion, Dated February 5, 2024 Common Stock Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-276872 The information contained in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been filed with the Securities and Exchange Commission and is effective. This preliminary prospectus supplement and the accompanying prospectus are not an offe
February 5, 2024	S-3ASR	As filed with the Securities and Exchange Commission on February 5, 2024 Table of Contents As filed with the Securities and Exchange Commission on February 5, 2024 Registration No.
February 5, 2024	EX-4.3	Form of Indenture Exhibit 4.3 4D MOLECULAR THERAPEUTICS, INC. INDENTURE Dated as of , 20 [ ] Trustee TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1. Definitions 1 Section 1.2. Other Definitions 4 Section 1.3. Incorporation by Reference of Trust Indenture Act 4 Section 1.4. Rules of Construction 5 ARTICLE II. THE SECURITIES 6 Section 2.1. Issuable in Series 6 Section
January 8, 2024	SC 13G/A	FDMT / 4D Molecular Therapeutics, Inc. / VIKING GLOBAL INVESTORS LP - SC 13G/A Passive Investment SC 13G/A 1 ef20018319sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS PURSUANT TO RULES 13d-1(b),(c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934* (Amendment No. 4) 4D Molecular Therapeutics, Inc. (Name of Issuer) Common stock, $0.0001 par value per s
January 8, 2024	SC 13G/A	FDMT / 4D Molecular Therapeutics, Inc. / VIKING GLOBAL INVESTORS LP - SC 13G/A Passive Investment SC 13G/A 1 ef20018316sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS PURSUANT TO RULES 13d-1(b),(c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934* (Amendment No. 3) 4D Molecular Therapeutics, Inc. (Name of Issuer) Common stock, $0.0001 par value per s
January 5, 2024	144	144 144 0001834021 XXXXXXXX LIVE 0001650648 4D Molecular Therapeutics, Inc. 001-39782 5858 Horton Street Suite 455 Emeryville CA 94608 1-510-505-2680 David Kirn Officer Class A Common Goldman Sachs & Co. LLC 200 West Street New York NY 10282 28237 553162.83 42753607 01/05/2024 NASD Class A Common 12/15/2020 Founder's Shares Issuer N 28237 12/15/2020 None N David Kirn 5858 Horton Street Suite 455 Emery
January 4, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 1, 2024 4D MOLECULAR THER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 1, 2024 4D MOLECULAR THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39782 47-3506994 (State or other jurisdiction of incorporation) (Co
November 22, 2023	EX-3.1	Amended and Restated Bylaws, as currently in effect. Exhibit 3.1 AMENDED AND RESTATED BYLAWS OF 4D MOLECULAR THERAPEUTICS, INC. (a Delaware corporation) TABLE OF CONTENTS Page ARTICLE I - CORPORATE OFFICES 1 1.1 REGISTERED OFFICE 1 1.2 OTHER OFFICES 1 ARTICLE II - MEETINGS OF STOCKHOLDERS 1 2.1 PLACE OF MEETINGS 1 2.2 ANNUAL MEETING 1 2.3 SPECIAL MEETING 1 2.4 ADVANCE NOTICE PROCEDURES FOR BUSINESS BROUGHT BEFORE A MEETING 2 2.5 ADVANCE NOTICE PROCE
November 22, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 16, 2023 4D MOLECULAR TH UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 16, 2023 4D MOLECULAR THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39782 47-3506994 (State or other jurisdiction of incorporation) (
November 9, 2023	EX-10.1	License Agreement between the Registrant and Astellas Gene Therapies, Inc., dated as of July 5, 2023 Certain confidential information contained in this document, marked by brackets and asterisk, has been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K, because the Company treats such information as private or confidential and the omitted information is not material.
November 9, 2023	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 09, 2023 4D Molecular Therapeutics Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39782 47-3506994 (State or Other Jurisdiction of Incorporation) (C
November 9, 2023	EX-99.1	4DMT Reports Third Quarter 2023 Financial Results and Operational Highlights Exhibit 99.1 4DMT Reports Third Quarter 2023 Financial Results and Operational Highlights • Rapidly advanced 4D-150 development for wet age-related macular degeneration (wet AMD): completed enrollment of PRISM Phase 2 Dose Expansion nearly two quarters earlier than expected and enrolled first patient in Population Extension cohort • Interim data update from 4D-150 PRISM Phase 2 Dose Expansion (n=5
November 9, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39782 4D Mol
September 13, 2023	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 11, 2023 4D MOLECULAR THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39782 47-3506994 (State or other jurisdiction of incorporation)
August 11, 2023	CORRESP	4D Molecular Therapeutics, Inc. 5858 Horton Street, #455 Emeryville, California 94608 4D Molecular Therapeutics, Inc. 5858 Horton Street, #455 Emeryville, California 94608 August 11, 2023 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549-6010 Attention: Jason Drory Re: 4D Molecular Therapeutics, Inc. Registration Statement on Form S-3 (Registration No. 333-273845) To the addre
August 9, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39782 4D Molecula
August 9, 2023	EX-4.5	Form of Indenture EX-4.5 Exhibit 4.5 4D MOLECULAR THERAPEUTICS, INC. INDENTURE Dated as of , 20 [ ] as Trustee TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1. Definitions 1 Section 1.2. Other Definitions 4 Section 1.3. Incorporation by Reference of Trust Indenture Act 4 Section 1.4. Rules of Construction 5 ARTICLE II. THE SECURITIES 5 Section 2.1. Issuable in Series 5 Sec
August 9, 2023	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 09, 2023 4D Molecular Therapeutics Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39782 47-3506994 (State or Other Jurisdiction of Incorporation) (Com
August 9, 2023	EX-99.1	4D Molecular Therapeutics Reports Second Quarter 2023 Financial Results and Operational Highlights Exhibit 99.1 4D Molecular Therapeutics Reports Second Quarter 2023 Financial Results and Operational Highlights • Presented positive interim data from intravitreal 4D-150 Phase 1/2 PRISM clinical trial for patients with wet age-related macular degeneration (wet AMD) • Completed target enrollment of 50 patients in the randomized Phase 2 Dose Expansion stage of the PRISM clinical trial in July, near
August 9, 2023	S-3	As filed with the Securities and Exchange Commission on August 9, 2023 S-3 Table of Contents As filed with the Securities and Exchange Commission on August 9, 2023 Registration No.
August 9, 2023	EX-FILING FEES	Fee Table Exhibit EX-FILING FEES Exhibit 107.1 Calculation of Filing Fee Tables Form S-3 (Form Type) 4D Molecular Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate(4
July 11, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 5, 2023 4D MOLECULAR THERAPE UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 5, 2023 4D MOLECULAR THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39782 47-3506994 (State or other jurisdiction of incorporation) (Commi
June 5, 2023	SC 13G	FDMT / 4D Molecular Therapeutics Inc / RA CAPITAL MANAGEMENT, L.P. - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* 4D MOLECULAR THERAPEUTICS, INC. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 35104E100 (CUSIP Number) May 25, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate
May 25, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 23, 2023 4D MOLECULAR THERAPE UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 23, 2023 4D MOLECULAR THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39782 47-3506994 (State or other jurisdiction of incorporation) (Commi
May 15, 2023	SC 13G	FDMT / 4D Molecular Therapeutics Inc / Venrock Healthcare Capital Partners III, L.P. - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* 4D Molecular Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 35104E100 (CUSIP Number) May 5, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate t
May 11, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39782 4D Molecul
May 11, 2023	EX-99	4D Molecular Therapeutics Reports First Quarter 2023 Financial Results and Operational Highlights Exhibit 99.1 4D Molecular Therapeutics Reports First Quarter 2023 Financial Results and Operational Highlights • Presented positive interim data from intravitreal 4D-150 Phase 1/2 PRISM clinical trial for wet age-related macular degeneration (wet AMD) at the 2023 ARVO Annual Meeting • On track for completion of enrollment of the Phase 2 Dose Expansion Stage of the PRISM clinical trial in Q3 2023 •
May 11, 2023	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2023 4D Molecular Therapeutics Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39782 47-3506994 (State or Other Jurisdiction of Incorporation) (Commis
May 9, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2023 4D MOLECULAR THERAPEU UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2023 4D MOLECULAR THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39782 47-3506994 (State or other jurisdiction of incorporation) (Commis
May 9, 2023	EX-1.1	Underwriting Agreement, dated as of May 4, 2023, among 4D Molecular Therapeutics, Inc. and Goldman Sachs & Co. LLC, BofA Securities, Inc. and Evercore Group, L.L.C. Exhibit 1.1 4D Molecular Therapeutics, Inc. Common Stock, par value $0.0001 per share Underwriting Agreement May 4, 2023 Goldman Sachs & Co. LLC BofA Securities, Inc. Evercore Group L.L.C. As representatives (the “Representatives”) of the several Underwriters named in Schedule I hereto c/o Goldman Sachs & Co. LLC 200 West Street New York, New York 10282 c/o BofA Securities, Inc. One Bryant Park Ne
May 8, 2023	424B5	Prospectus Supplement to Prospectus Dated April 15, 2022 7,500,000 Shares Common Stock 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-263925 Prospectus Supplement to Prospectus Dated April 15, 2022 7,500,000 Shares Common Stock 4D Molecular Therapeutics, Inc. is offering 7,500,000 shares of its common stock, par value $0.0001 per share. Our common stock is listed on the Nasdaq Global Select Market under the symbol “FDMT.” On May 4, 2023, the last repor
May 4, 2023	424B5	Subject to Completion, Dated May 4, 2023 Prospectus Supplement to Prospectus Dated April 15, 2022 Common Stock 424B5 1 d557482d424b5.htm 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-263925 The information contained in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been filed with the Securities and Exchange Commission and is effective. This preliminary prospectus supplement and the accompa
May 4, 2023	S-8 POS	As filed with the Securities and Exchange Commission on May 3, 2023 S-8 POS As filed with the Securities and Exchange Commission on May 3, 2023 Registration No.
April 12, 2023	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Pro
April 12, 2023	DEF 14A	Schedule 14A DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
March 15, 2023	EX-99	4D Molecular Therapeutics Reports Full Year 2022 Financial Results and Operational Highlights Exhibit 99.1 4D Molecular Therapeutics Reports Full Year 2022 Financial Results and Operational Highlights • Provided updates on clinical pipeline, including 4D-150 for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME), 4D-710 for cystic fibrosis lung disease, and 4D-310 for Fabry disease cardiomyopathy • Demonstrated robust clinical gene delivery, tolerability and in
March 15, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 15, 2023 4D Molecular Therapeutics Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39782 47-3506994 (State or Other Jurisdiction of Incorporation) (Comm
March 15, 2023	EX-4	Description of Securities of the Registrant. Exhibit 4.1 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of December 31, 2022, 4D Molecular Therapeutics, Inc. had one class of common stock registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). The following summary describes our capital stock and the material provisions of our
March 15, 2023	10-K	Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39782 4D Molecular Th
March 15, 2023	EX-FILING FEES	Calculation of Filing Fee Table EX-FILING FEES Exhibit 107.1 Calculation of Filing Fee Tables Form S-8 (Form Type) 4D Molecular Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1—Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount to be Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee E
March 15, 2023	S-8	As filed with the Securities and Exchange Commission on March 15, 2023 S-8 As filed with the Securities and Exchange Commission on March 15, 2023 Registration No.
February 14, 2023	SC 13G/A	FDMT / 4D Molecular Therapeutics Inc / Deep Track Capital, LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No.
February 8, 2023	SC 13G/A	FDMT / 4D Molecular Therapeutics Inc / Kirn David - SC 13G/A Passive Investment SC 13G/A United States Securities and Exchange Commission Washington, D.C. 20549 Schedule 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to § 240.13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2)* 4D Molecular Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 (Title of
February 3, 2023	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 2, 2023 4D MOLECULAR THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39782 47-3506994 (State or other jurisdiction of incorporation) (C
January 26, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2023 4D Molecular Ther UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2023 4D Molecular Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39782 47-3506994 (State or other jurisdiction of incorporation) (Co
November 9, 2022	EX-99.1	4D Molecular Therapeutics Reports Third Quarter 2022 Financial Results - Interim clinical trial data from 4DMT’s Phase 1/2 clinical trial of 4D-710 for the treatment of cystic fibrosis lung disease was presented at North American Cystic Fibrosis Conf Exhibit 99.1 4D Molecular Therapeutics Reports Third Quarter 2022 Financial Results - Interim clinical trial data from 4DMT?s Phase 1/2 clinical trial of 4D-710 for the treatment of cystic fibrosis lung disease was presented at North American Cystic Fibrosis Conference on November 3, 2022 - Cash, cash equivalents and marketable securities sufficient to fund operations into the first half of 2025 E
November 9, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 09, 2022 4D Molecular Therapeutics Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39782 47-3506994 (State or Other Jurisdiction of Incorporation) (C
November 8, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO . Commission File Number: 001-39782 4D
September 27, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 23, 2022 4D MOLECULAR THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39782 47-3506994 (State or other jurisdiction of incorporation)
September 1, 2022	CORRESP	4D Molecular Therapeutics, Inc. 5858 Horton Street, #455 Emeryville, California 94608 4D Molecular Therapeutics, Inc. 5858 Horton Street, #455 Emeryville, California 94608 September 1, 2022 VIA EDGAR AND E-MAIL United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549-6010 Attention: Dillon Hagius Re: 4D Molecular Therapeutics, Inc. Registration Statement on Form S-3 (Registration No. 333-26701
August 23, 2022	S-3	As filed with the Securities and Exchange Commission on August 22, 2022 Table of Contents As filed with the Securities and Exchange Commission on August 22, 2022 Registration No.
August 23, 2022	EX-FILING FEES	Fee Table Exhibit Exhibit 107.1 Calculation of Filing Fee Tables Form S-3 (Form Type) 4D Molecular Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Regist
August 11, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2022 4D Molecular Therapeutics Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39782 47-3506994 (State or Other Jurisdiction of Incorporation) (Com
August 11, 2022	EX-99.1	4D Molecular Therapeutics Reports Second Quarter 2022 Financial Results and Provides 4D-310 Program Update Exhibit 99.1 4D Molecular Therapeutics Reports Second Quarter 2022 Financial Results and Provides 4D-310 Program Update ? Five clinical-stage product candidates on track for multiple clinical data updates in 2023 ? Cash, cash equivalents and marketable securities sufficient to fund operations into the first half of 2025 ? 4D-310 Phase 1/2 clinical trial eligible patient population expanded to incl
August 11, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO . Commission File Number: 001-39782 4D Molec
June 21, 2022	EX-3.1	Amended and Restated Bylaws. Exhibit 3.1 AMENDED AND RESTATED BYLAWS OF 4D MOLECULAR THERAPEUTICS, INC. (a Delaware corporation) TABLE OF CONTENTS Page ARTICLE I - CORPORATE OFFICES 1 1.1 REGISTERED OFFICE 1 1.2 OTHER OFFICES 1 ARTICLE II - MEETINGS OF STOCKHOLDERS 1 2.1 PLACE OF MEETINGS 1 2.2 ANNUAL MEETING 1 2.3 SPECIAL MEETING 1 2.4 ADVANCE NOTICE PROCEDURES FOR BUSINESS BROUGHT BEFORE A MEETING 2 2.5 ADVANCE NOTICE PROCE
June 21, 2022	SC 13G/A	FDMT / 4D Molecular Therapeutics Inc / BIOTECHNOLOGY VALUE FUND L P - AMENDMENT NO. 1 TO SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 1)1 4D Molecular Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 35104E 10 0 (CUS
June 21, 2022	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 14, 2022 4D MOLECULAR THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39782 47-3506994 (State or other jurisdiction of incorporation) (Comm
May 27, 2022	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 23, 2022 4D MOLECULAR THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39782 47-3506994 (State or other jurisdiction of incorporation) (Commi
May 12, 2022	EX-10.1	Restated Amended and Restated Non-Employee Director Compensation Policy. Exhibit 10.1 4D Molecular Therapeutics, Inc. Amended and Restated Non-Employee Director Compensation Program This 4D Molecular Therapeutics, Inc. (the ?Company?) Non-Employee Director Compensation Program (this ?Program?) has been adopted under the Company?s 2019 Incentive Award Plan (the ?Plan?) and has been amended and restated effective as of March 21, 2022 (the ?Effective Date?). Capitalized t
May 12, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2022 4D Molecular Therapeutics Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39782 47-3506994 (State or Other Jurisdiction of Incorporation) (Commis
May 12, 2022	EX-99.1	4D Molecular Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Updates Exhibit 99.1 4D Molecular Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Updates Emeryville, CA ? May 12, 2022 ? 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT), a clinical-stage biotherapeutics company harnessing the power of directed evolution for targeted genetic medicines, announced first quarter 2022 financial results and provided corporate updates. ?We made s
May 12, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39782 4D Molecul
April 13, 2022	CORRESP	4D Molecular Therapeutics, Inc. 5858 Horton Street, #455 Emeryville, California 94608 4D Molecular Therapeutics, Inc. 5858 Horton Street, #455 Emeryville, California 94608 April 13, 2022 VIA EDGAR AND E-MAIL United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549-6010 Attention: Alan Campbell Re: 4D Molecular Therapeutics, Inc. Registration Statement on Form S-3 (Registration No. 333-263925)
April 13, 2022	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defi
April 13, 2022	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State
March 29, 2022	EX-1.1	Open Market Sale AgreementSM by and between the Registrant and Jefferies LLC Exhibit 1.1 OPEN MARKET SALE AGREEMENTSM March 28, 2022 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: 4D Molecular Therapeutics, Inc., a Delaware corporation (the ?Company?), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the ?Agent?), shares of the Company?s
March 29, 2022	EX-FILING FEES	Fee Table Exhibit Exhibit 107.1 Calculation of Filing Fee Tables Form S-3 (Form Type) 4D Molecular Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Regist
March 29, 2022	S-3	As filed with the Securities and Exchange Commission on March 28, 2022 Table of Contents As filed with the Securities and Exchange Commission on March 28, 2022 Registration No.
March 29, 2022	EX-4.3	Form of Indenture Exhibit 4.3 4D MOLECULAR THERAPEUTICS, INC. INDENTURE Dated as of , 20 [ ], as Trustee TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1. Definitions 1 Section 1.2. Other Definitions 4 Section 1.3. Incorporation by Reference of Trust Indenture Act 4 Section 1.4. Rules of Construction 5 ARTICLE II. THE SECURITIES 5 Section 2.1. Issuable in Series 5 Section 2
March 28, 2022	EX-4.1	Exhibit 4.1 Exhibit 4.1 DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of December 31, 2021, 4D Molecular Therapeutics, Inc. had one class of common stock registered under Section 12 of the Securities Exchange Act of 1934, as amended (the ?Exchange Act?). The following summary describes our capital stock and the material provisions of our
March 28, 2022	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39782 4D Molecular Th
March 28, 2022	EX-FILING FEES	Calculation of Filing Fee Table Exhibit 107.1 Calculation of Filing Fee Tables Form S-8 (Form Type) 4D Molecular Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1?Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount to be Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common st
March 28, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 28, 2022 4D Molecular Therapeutics Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39782 47-3506994 (State or Other Jurisdiction of Incorporation) (Comm
March 28, 2022	S-8	As filed with the Securities and Exchange Commission on March 28, 2022 As filed with the Securities and Exchange Commission on March 28, 2022 Registration No.
March 28, 2022	EX-99.1	4D Molecular Therapeutics Reports Full Year 2021 Financial Results and Operational Highlights — Provided clinical data updates on three programs, including first clinical data on 4D-310 for Fabry disease and 4D-125 and 4D-110 for inherited retinal dy Exhibit 99.1 4D Molecular Therapeutics Reports Full Year 2021 Financial Results and Operational Highlights ? Provided clinical data updates on three programs, including first clinical data on 4D-310 for Fabry disease and 4D-125 and 4D-110 for inherited retinal dystrophies, each demonstrating preliminary evidence of clinical activity ? Advanced two additional programs into clinical development: R10
February 22, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 17, 2022 4D MOLECULAR THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39782 47-3506994 (State or other jurisdiction of incorporation) (
February 14, 2022	SC 13G/A	FDMT / 4D Molecular Therapeutics Inc / Deep Track Capital, LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No.
February 14, 2022	SC 13G/A	FDMT / 4D Molecular Therapeutics Inc / Kirn David - SC 13G/A Passive Investment SC 13G/A 1 d275210dsc13ga.htm SC 13G/A United States Securities and Exchange Commission Washington, D.C. 20549 Schedule 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to § 240.13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* 4D Molecular Therapeutics Inc. (Name of Issuer) Common Stock
February 14, 2022	SC 13G/A	FDMT / 4D Molecular Therapeutics Inc / SCHAFFER DAVID - SC 13G/A Passive Investment United States Securities and Exchange Commission Washington, D.C. 20549 Schedule 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to ? 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to ? 240.13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* 4D Molecular Therapeutics Inc. (Name of Issuer) Common Stock, par value $0.0001 (Title of Class of
February 14, 2022	SC 13G/A	FDMT / 4D Molecular Therapeutics Inc / VIKING GLOBAL INVESTORS LP - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS PURSUANT TO RULES 13d-1(b),(c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934* (Amendment No. 2) 4D Molecular Therapeutics, Inc. (Name of Issuer) Common stock, $0.0001 par value per share (Title of Class of Securities) 35104
February 11, 2022	SC 13G/A	FDMT / 4D Molecular Therapeutics Inc / PFIZER INC - SC 13G/A 4D MOLECULAR Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 1) 1 4D Molecular Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 35104E100 (CUSIP Number) D
February 9, 2022	SC 13G/A	FDMT / 4D Molecular Therapeutics Inc / FMR LLC Passive Investment SCHEDULE 13G Amendment No. 1 4D MOLECULAR THERAPEUTICS INC COMMON STOCK Cusip #35104E100 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #35104E100 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 207,559 Item 6: 0 Item 7: 1,140,174 Item 8: 0 Item 9: 1,140,174 It
January 11, 2022	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2022 4D MOLECULAR THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39782 47-3506994 (State or other jurisdiction of incorporation) (C
January 11, 2022	EX-99.1	Legal Disclaimer This Presentation contains forward looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this Presentation, including statements regarding our cli Exhibit 99.1 Harnessing the Power of Directed Evolution for Targeted Gene Therapies Corporate Presentation \| January 2022 ? 2021 4D Molecular Therapeutics. All Rights Reserved. Legal Disclaimer This Presentation contains forward looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this Presentation, including s
November 10, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2021 4D Molecular Therapeutics Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39782 47-3506994 (State or Other Jurisdiction of Incorporation) (C
November 10, 2021	EX-99.1	4D Molecular Therapeutics Reports Financial Results for the Third Quarter of 2021 and Provides Operational Highlights Exhibit 99.1 4D Molecular Therapeutics Reports Financial Results for the Third Quarter of 2021 and Provides Operational Highlights Emeryville, CA ? November 10, 2021 ? 4D Molecular Therapeutics (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therapies, announced financial results for the third quarter of 2021, and provided operatio
November 10, 2021	EX-10.4	Change in Control and Severance Agreement, dated September 22, 2021, by and between Fred Kamal and 4D Molecular Therapeutics, Inc. Exhibit 10.4 4D MOLECULAR THERAPEUTICS, INC. CHANGE IN CONTROL AND SEVERANCE AGREEMENT This Change in Control and Severance Agreement (the ?Agreement?) is made and entered into by and between Fariborz Kamal (?Executive?) and 4D Molecular Therapeutics, Inc. (the ?Company?), effective as of the latest date set forth by the signatures of the parties hereto below (the ?Effective Date?). Background A.
November 10, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39782 4D Mol
November 4, 2021	SC 13G	FDMT / 4D Molecular Therapeutics Inc / Deep Track Capital, LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.
November 1, 2021	424B4	4,750,000 Shares Common Stock Table of Contents Filed pursuant to Rule 424(b)(4) Registration No. 333-260508 4,750,000 Shares Common Stock We are offering 4,750,000 shares of our common stock. Our common stock is listed on the Nasdaq Global Select Market under the symbol ?FDMT.? On October 28, 2021, the last reported sale price of our common stock on the Nasdaq Global Select Market was $30.85 per share. We are an ?emerging gro
October 26, 2021	CORRESP	4D Molecular Therapeutics, Inc. 5858 Horton Street, #455 Emeryville, California 94608 4D Molecular Therapeutics, Inc. 5858 Horton Street, #455 Emeryville, California 94608 October 26, 2021 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549-6010 Attention: Michael Davis Re: 4D Molecular Therapeutics, Inc. Registration Statement on Form S-1 (Registration No. 333-260508) Ladies an
October 26, 2021	S-1	As filed with the Securities and Exchange Commission on October 26, 2021. Table of Contents As filed with the Securities and Exchange Commission on October 26, 2021.
October 26, 2021	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 25, 2021 4D MOLECULAR THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39782 47-3506994 (State or other jurisdiction of incorporation) (C
October 26, 2021	EX-1.1	Form of Underwriting Agreement. Exhibit 1.1 4D Molecular Therapeutics, Inc. Common Stock, par value $0.0001 per share Underwriting Agreement October [?], 2021 Goldman Sachs & Co. LLC SVB Leerink LLC Evercore Group L.L.C. As representatives (the ?Representatives?) of the several Underwriters named in Schedule I hereto c/o Goldman Sachs & Co. LLC 200 West Street New York, New York 10282 c/o SVB Leerink LLC 1301 Avenue of the Ameri
October 26, 2021	CORRESP	[signature page follows] CORRESP 1 filename1.htm October 26, 2021 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-6010 Attention: Michael Davis Re: 4D Molecular Therapeutics, Inc. Registration Statement on Form S-1 (File No. 333-260508) Ladies and Gentlemen: Pursuant to Rule 460 of the General Rules and Regulations under the Securities Act of 1933,
October 13, 2021	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 10, 2021 4D MOLECULAR THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39782 47-3506994 (State or other jurisdiction of incorporation) (C
October 8, 2021	DRS	Confidential Treatment Requested by 4D Molecular Therapeutics, Inc. Pursuant to 17 C.F.R. Section 200.83 As confidentially submitted to the Securities and Exchange Commission on October 7, 2021. Table of Contents Confidential Treatment Requested by 4D Molecular Therapeutics, Inc.
September 24, 2021	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 22, 2021 4D MOLECULAR THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39782 47-3506994 (State or other jurisdiction of incorporation)
September 24, 2021	EX-10.1	Change in Control and Severance Agreement, dated September 22, 2021, by and between David Kirn and 4D Molecular Therapeutics, Inc. Exhibit 10.1 4D MOLECULAR THERAPEUTICS, INC. CHANGE IN CONTROL AND SEVERANCE AGREEMENT This Change in Control and Severance Agreement (the ?Agreement?) is made and entered into by and between David Kirn, M.D. (?Executive?) and 4D Molecular Therapeutics, Inc. (the ?Company?), effective as of the latest date set forth by the signatures of the parties hereto below (the ?Effective Date?). Background A
September 24, 2021	EX-10.2	Change in Control and Severance Agreement, dated September 22, 2021, by and between August Moretti and 4D Molecular Therapeutics, Inc. Exhibit 10.2 4D MOLECULAR THERAPEUTICS, INC. CHANGE IN CONTROL AND SEVERANCE AGREEMENT This Change in Control and Severance Agreement (the ?Agreement?) is made and entered into by and between August Moretti (?Executive?) and 4D Molecular Therapeutics, Inc. (the ?Company?), effective as of the latest date set forth by the signatures of the parties hereto below (the ?Effective Date?). Background A.
September 24, 2021	EX-10.3	Change in Control and Severance Agreement, dated September 22, 2021, by and between Robert Stephen Fishman and 4D Molecular Therapeutics, Inc. Exhibit 10.3 4D MOLECULAR THERAPEUTICS, INC. CHANGE IN CONTROL AND SEVERANCE AGREEMENT This Change in Control and Severance Agreement (the ?Agreement?) is made and entered into by and between Robert Stephen Fishman (?Executive?) and 4D Molecular Therapeutics, Inc. (the ?Company?), effective as of the latest date set forth by the signatures of the parties hereto below (the ?Effective Date?). Backgr
August 12, 2021	EX-99.1	4D Molecular Therapeutics Reports Financial Results for the Second Quarter of 2021 and Provides Operational Highlights Exhibit 99.1 4D Molecular Therapeutics Reports Financial Results for the Second Quarter of 2021 and Provides Operational Highlights Emeryville, CA ? August 12, 2021 ? 4D Molecular Therapeutics (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therapies, announced financial results for the second quarter of 2021, and provided operatio
August 12, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39782 4D Molecula
August 12, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2021 4D Molecular Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39782 47-3506994 (State or Other Jurisdiction of Incorporation) (Co
July 6, 2021	SC 13G	US35104E1001 / Common Stock / BIOTECHNOLOGY VALUE FUND L P - THE SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. )1 4D Molecular Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 35104E 10 0 (CUSI
July 6, 2021	EX-99.1	Joint Filing Agreement Exhibit 99.1 Joint Filing Agreement The undersigned hereby agree that the Statement on Schedule 13G dated July 6, 2021 with respect to the shares of Common Stock, par value $0.0001 per share of 4D Molecular Therapeutics, Inc., a Delaware corporation, and any further amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in
June 25, 2021	8-K	Termination of a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 18, 2021 4D Molecular Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39782 47-3506994 (State or Other Jurisdiction of Incorporation) (Comm
June 25, 2021	EX-99.1	4D Molecular Therapeutics Announces Rare Disease Ophthalmology Product Candidate Portfolio Update, Including Initial Clinical Safety and Tolerability Data for 4D-110 for Choroideremia and 4D-125 for XLRP, and Termination of Roche Collaboration and Li Exhibit 99.1 4D Molecular Therapeutics Announces Rare Disease Ophthalmology Product Candidate Portfolio Update, Including Initial Clinical Safety and Tolerability Data for 4D-110 for Choroideremia and 4D-125 for XLRP, and Termination of Roche Collaboration and License Agreement - 4D-110: Initial clinical safety data at both of the two dose levels in the Phase 1 clinical trial indicate that 4D-110
May 20, 2021	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 17, 2021 4D Molecular Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39782 47-3506994 (State or Other Jurisdiction of Incorporation) (Commi
May 13, 2021	EX-99.1	4D Molecular Therapeutics Reports Financial Results for the First Quarter of 2021 and Provides Operational Highlights Exhibit 99.1 4D Molecular Therapeutics Reports Financial Results for the First Quarter of 2021 and Provides Operational Highlights Emeryville, CA ? May 13, 2021 ? 4D Molecular Therapeutics (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therapies, announced financial results for the first quarter of 2021, and provided operational h
May 13, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2021 4D Molecular Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39782 47-3506994 (State or Other Jurisdiction of Incorporation) (Commi
May 13, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39782 4D Molecul
April 6, 2021	DEF 14A	Schedule 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State
April 6, 2021	DEFA14A	- DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin
March 25, 2021	EX-4.1	Description of Securities of the Registrant. Exhibit 4.1 DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of December 31, 2020, 4D Molecular Therapeutics, Inc. had one class of common stock registered under Section 12 of the Securities Exchange Act of 1934, as amended (the ?Exchange Act?). The following summary describes our capital stock and the material provisions of our
March 25, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 25, 2021 4D MOLECULAR THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39782 47-3506994 (State or other jurisdiction of incorporation) (Com
March 25, 2021	S-8	- S-8 As filed with the Securities and Exchange Commission on March 25, 2021 Registration No.
March 25, 2021	EX-99.1	4D Molecular Therapeutics Reports Financial Results for the Year Ended December 31, 2020 and Provides Operational Highlights - First patient dosed in the 4D-310 Phase 1/2 clinical trial in Fabry disease - Intravitreal product candidates, 4D-125 for t EX-99.1 Exhibit 99.1 4D Molecular Therapeutics Reports Financial Results for the Year Ended December 31, 2020 and Provides Operational Highlights - First patient dosed in the 4D-310 Phase 1/2 clinical trial in Fabry disease - Intravitreal product candidates, 4D-125 for the treatment of XLRP and 4D-110 for the treatment of choroideremia, completed dose escalation portion of Phase 1/2 clinical trial
March 25, 2021	10-K	Annual Report - 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39782 4D Molecular Th
February 16, 2021	SC 13G/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Amendment No. 1) UNDER THE SECURITIES EXCHANGE ACT OF 19341 4D Molecular Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 (Title of Class of Securi UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Amendment No.
February 16, 2021	SC 13G	United States Securities and Exchange Commission Washington, D.C. 20549 Schedule 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to § 240.13d-2 UNDER THE SC 13G United States Securities and Exchange Commission Washington, D.C. 20549 Schedule 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to § 240.13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* 4D Molecular Therapeutics Inc. (Name of Issuer) Common Stock, par value $0.0001 (Title of Cla
February 16, 2021	SC 13G	United States Securities and Exchange Commission Washington, D.C. 20549 Schedule 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to § 240.13d-2 UNDER THE SC 13G 1 d132566dsc13g.htm SC 13G United States Securities and Exchange Commission Washington, D.C. 20549 Schedule 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to § 240.13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* 4D Molecular Therapeutics Inc. (Name of Issuer) Common Stock, par
February 16, 2021	SC 13G/A	SCHEDULE 13G/A INFORMATION TO BE INCLUDED IN STATEMENTS PURSUANT TO RULES 13d-1(b),(c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934* (Amendment No. 1) 4D Molecular Therapeutics, Inc. (Name of Issuer SC 13G/A 1 fdmt-sc13ga123120.htm AMENDMENT NO. 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A INFORMATION TO BE INCLUDED IN STATEMENTS PURSUANT TO RULES 13d-1(b),(c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934* (Amendment No. 1) 4D Molecular Therapeutics, Inc. (Name of Issuer) Common stock, $0.0001 par v
February 16, 2021	EX-99.1	JOINT FILING AGREEMENT CUSIP No. 35104E100 EXHIBIT 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the statement on Schedule 13G to which this Agreement is annexed as Exhibit 99.1, and any amendments thereto, is and will be filed on behalf of each of them in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended. Dated: February 12, 2021 PFIZER INC. By: /s/ Su
February 16, 2021	SC 13G	(Amendment No. ) * CUSIP No. 35104E100 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b),(c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. ) * 4D Molecular Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 35104E100 (CUSIP Numbe
December 23, 2020	SC 13G	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Amendment No. __) UNDER THE SECURITIES EXCHANGE ACT OF 19341 4D Molecular Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 (Title of Class of Secur UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Amendment No.
December 23, 2020	EX-99.1	Joint Filing Agreement Exhibit 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that statements on Schedules 13G and/or 13D and Forms 3, 4 and 5 with respect to the securities of 4D Molecular Therapeutics, Inc. and any amendments thereto signed by each of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k) promulgated under the Se
December 21, 2020	SC 13G	SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS PURSUANT TO RULES 13d-1(b),(c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934* 4D Molecular Therapeutics, Inc. (Name of Issuer) Common stock, $0.0 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS PURSUANT TO RULES 13d-1(b),(c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934* 4D Molecular Therapeutics, Inc. (Name of Issuer) Common stock, $0.0001 par value per share (Title of Class of Securities) 35104E100 (CUSIP Number
December 15, 2020	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits, Other Events - 8-K 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 15, 2020 4D MOLECULAR THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39782 47-3506994 (State or other jurisdiction of incorporatio
December 15, 2020	S-8	- S-8 S-8 As filed with the Securities and Exchange Commission on December 15, 2020 Registration No.
December 15, 2020	EX-99.3	2020 Employee Stock Purchase Plan. EX-99.3 Exhibit 99.3 4D MOLECULAR THERAPEUTICS, INC. 2020 EMPLOYEE STOCK PURCHASE PLAN ARTICLE I. PURPOSE The Plan’s purpose is to assist employees of the Company and its Designated Subsidiaries in acquiring a stock ownership interest in the Company pursuant to a plan which is intended to qualify as an “employee stock purchase plan” under Section 423 of the Code, and to help such employees provide
December 15, 2020	EX-3.1	Amended and Restated Certificate of Incorporation, as currently in effect. EX-3.1 Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF 4D MOLECULAR THERAPEUTICS, INC. 4D Molecular Therapeutics, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), certifies that: 1. The name of the Corporation is 4D Molecular Therapeutics, Inc. The Corporation’s original Certificate of Incorporation was filed with the Secretar
December 15, 2020	EX-99.2(A)	2020 Equity Incentive Award Plan. EX-99.2(a) Exhibit 99.2(a) 4D MOLECULAR THERAPEUTICS, INC. 2020 INCENTIVE AWARD PLAN ARTICLE I. PURPOSE The Plan’s purpose is to enhance the Company’s ability to attract, retain and motivate persons who make (or are expected to make) important contributions to the Company by providing these individuals with equity ownership opportunities. ARTICLE II. DEFINITIONS As used in the Plan, the following
December 15, 2020	EX-3.2	Amended and Restated Bylaws, as currently in effect. EX-3.2 Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF 4D MOLECULAR THERAPEUTICS, INC. (a Delaware corporation) TABLE OF CONTENTS Page ARTICLE I - CORPORATE OFFICES 1 1.1 REGISTERED OFFICE 1 1.2 OTHER OFFICES 1 ARTICLE II - MEETINGS OF STOCKHOLDERS 1 2.1 PLACE OF MEETINGS 1 2.2 ANNUAL MEETING 1 2.3 SPECIAL MEETING 1 2.4 ADVANCE NOTICE PROCEDURES FOR BUSINESS BROUGHT BEFORE A MEETING 2 2.5 ADVANCE NOTIC
December 14, 2020	424B4	8,400,000 Shares Common Stock 424B4 Table of Contents Filed Pursuant to Rule 424(b)(4) Registration No. 333-250150 8,400,000 Shares Common Stock This is the initial public offering of shares of common stock of 4D Molecular Therapeutics, Inc. We are offering 8,400,000 shares of our common stock. Prior to this offering, there has been no public market for our common stock. The initial public offering price is $23.00 per share. O
December 10, 2020	S-1/A	Form S-1 Table of Contents As filed with the Securities and Exchange Commission on December 10, 2020.
December 10, 2020	S-1MEF	As filed with the Securities and Exchange Commission on December 10, 2020 As filed with the Securities and Exchange Commission on December 10, 2020 Registration No.
December 8, 2020	CORRESP	4D Molecular Therapeutics, Inc. 5858 Horton Street, #455 Emeryville, California 94608 CORRESP 1 filename1.htm 4D Molecular Therapeutics, Inc. 5858 Horton Street, #455 Emeryville, California 94608 December 8, 2020 VIA EDGAR AND E-MAIL United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549-6010 Attention: Ada Sarmento Suzanne Hayes Jenn Do Jeanne Baker Re: 4D Molecular Therapeutics, Inc. Regis
December 8, 2020	CORRESP	[signature page follows] December 8, 2020 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.
December 8, 2020	8-A12B	Form 8-A 8-A12B UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 4D MOLECULAR THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 47-3506994 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer I
December 7, 2020	EX-10.8	Exclusive License and Bailment Agreement, dated December 19, 2013, between the Registrant and The Regents of the University of California. EX-10.8 [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. Exhibit 10.8 Agreement Control No. 2014-03-0089 UNIVERSITY OF CALIFORNIA, BERKELEY OFFICE OF TECHNOLOGY LICENSING EXCLUSIVE LICENSE AND BAILMENT AGREEMENT BETWEEN
December 7, 2020	EX-10.11	Employment Agreement, dated January 15, 2019 between Peter Francis, M.D., Ph.D. and the Registrant. EX-10.11 Exhibit 10.11 4D Molecular Therapeutics, Inc. Employment Agreement This Employment Agreement (this “Agreement”), dated as of January 15, 2019, is made by and between 4D Molecular Therapeutics, Inc., a Delaware corporation (together with any successor thereto, the “Company”), and Peter Francis, M.D. (“Executive”) (collectively referred to as the “Parties” or individually referred to as a “
December 7, 2020	EX-10.2(A)	2020 Incentive Award Plan. EX-10.2(a) Exhibit 10.2(a) 4D MOLECULAR THERAPEUTICS, INC. 2020 INCENTIVE AWARD PLAN ARTICLE I. PURPOSE The Plan’s purpose is to enhance the Company’s ability to attract, retain and motivate persons who make (or are expected to make) important contributions to the Company by providing these individuals with equity ownership opportunities. ARTICLE II. DEFINITIONS As used in the Plan, the following
December 7, 2020	EX-10.9	Exclusive License and Bailment Agreement, dated December 19, 2013, between the Registrant and The Regents of the University of California. EX-10.9 [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. Exhibit 10.9 Agreement Control No. 2014-16-0090 UNIVERSITY OF CALIFORNIA, BERKELEY OFFICE OF TECHNOLOGY LICENSING EXCLUSIVE LICENSE AND BAILMENT AGREEMENT BETWEEN
December 7, 2020	EX-4.2	Form of Common Stock Certificate. EX-4.2 Exhibit 4.2 DE L AWA RE SEAL 4D MOLECULAR THERAPEUTICS, INC. CORPORATE Mrach 11, 2015 4D FULLY PAID AND NONASSESSABLE SHARES OF COMMON STOCK, $0.0001 PAR VALUE PER SHARE, OF 4D Molecular Therapeutics, Inc. transferable on the books of the Corporation in person or by duly authorized attorney upon surrender of this Certificate properly endorsed. This Certificate is not valid until countersign
December 7, 2020	EX-10.10	Offer Letter, dated March 20, 2015 between David Kirn, M.D. and the Registrant. EX-10.10 Exhibit 10.10 March 20, 2015 David Kirn, MD Dear David: Position. We are pleased to confirm the terms of the offer to you to join 4D Molecular Therapeutics, Inc. (the “Company”) as an employee, in the position of Chief Executive Officer and President. In this role, you will be reporting to the Board of Directors of the Company. You will have the customary duties and responsibilities of th
December 7, 2020	EX-10.2(B)	Form of Stock Option Grant Notice and Stock Option Agreement under the 2020 Incentive Award Plan. EX-10.2(b) Exhibit 10.2(b) 4D MOLECULAR THERAPEUTICS, INC. 2020 INCENTIVE AWARD PLAN STOCK OPTION GRANT NOTICE 4D Molecular Therapeutics, Inc., a Delaware corporation, (the “Company”), pursuant to its 2020 Incentive Award Plan, as may be amended from time to time (the “Plan”), hereby grants to the holder listed below (“Participant”), an option to purchase the number of shares of the Company’s Comm
December 7, 2020	S-1/A	Form S-1 S-1/A Table of Contents As filed with the Securities and Exchange Commission on December 7, 2020.
December 7, 2020	EX-1.1	Form of Underwriting Agreement. EX-1.1 Exhibit 1.1 4D Molecular Therapeutics, Inc. Common Stock, par value $0.0001 per share Underwriting Agreement [●], 2020 Goldman Sachs & Co. LLC BofA Securities, Inc. Evercore Group L.L.C. As representatives (the “Representatives”) of the several Underwriters named in Schedule I hereto c/o Goldman Sachs & Co. LLC 200 West Street New York, New York 10282 c/o BofA Securities, Inc. One Bryant Pa
December 7, 2020	EX-10.12	Offer Letter, dated January 4, 2019 between August Moretti and the Registrant. EX-10.12 Exhibit 10.12 January 4, 2019 August Moretti [*****] Dear August: We are pleased to make you the following offer of employment. We believe you will play an important and meaningful role in our mission of curing people of genetic diseases. Position. Your title will be Chief Financial Officer. You will be reporting to the CEO, David Kirn. Your employment commencement date will be January 7,
December 7, 2020	CORRESP	* * * CORRESP 1 filename1.htm 140 Scott Drive Menlo Park, California 94025 Tel: +1.650.328.4600 Fax: +1.650.463.2600 www.lw.com FIRM / AFFILIATE OFFICES Beijing Moscow Boston Munich Brussels New York Century City Orange County Chicago Paris December 7, 2020 Dubai Riyadh Düsseldorf San Diego Frankfurt San Francisco Hamburg Seoul Hong Kong Shanghai Houston Silicon Valley London Singapore Los Angeles Tokyo
December 7, 2020	EX-3.4	Form of Amended and Restated Bylaws, to be in effect immediately prior to the consummation of this offering. EX-3.4 Exhibit 3.4 AMENDED AND RESTATED BYLAWS OF 4D MOLECULAR THERAPEUTICS, INC. (a Delaware corporation) TABLE OF CONTENTS Page ARTICLE I - CORPORATE OFFICES 1 1.1 REGISTERED OFFICE 1 1.2 OTHER OFFICES 1 ARTICLE II - MEETINGS OF STOCKHOLDERS 1 2.1 PLACE OF MEETINGS 1 2.2 ANNUAL MEETING 1 2.3 SPECIAL MEETING 1 2.4 ADVANCE NOTICE PROCEDURES FOR BUSINESS BROUGHT BEFORE A MEETING 2 2.5 ADVANCE NOTIC
December 7, 2020	EX-10.3	2020 Employee Stock Purchase Plan. EX-10.3 Exhibit 10.3 4D MOLECULAR THERAPEUTICS, INC. 2020 EMPLOYEE STOCK PURCHASE PLAN ARTICLE I. PURPOSE The Plan’s purpose is to assist employees of the Company and its Designated Subsidiaries in acquiring a stock ownership interest in the Company pursuant to a plan which is intended to qualify as an “employee stock purchase plan” under Section 423 of the Code, and to help such employees provide
December 7, 2020	EX-10.2(C)	Form of Restricted Stock Award Grant Notice and Restricted Stock Award Agreement under the 2020 Incentive Award Plan. EX-10.2(c) Exhibit 10.2(c) 4D MOLECULAR THERAPEUTICS, INC. 2020 INCENTIVE AWARD PLAN RESTRICTED STOCK AWARD GRANT NOTICE 4D Molecular Therapeutics, Inc., a Delaware corporation, (the “Company”), pursuant to its 2020 Incentive Award Plan, as amended from time to time (the “Plan”), hereby grants to the holder listed below (the “Participant”) the number of shares of the Company’s Common Stock set for
December 7, 2020	EX-10.2(D)	Form of Restricted Stock Unit Award Grant Notice and Restricted Stock Unit Award Agreement under the 2020 Incentive Award Plan. EX-10.2(d) Exhibit 10.2(d) 4D MOLECULAR THERAPEUTICS, INC. 2020 INCENTIVE AWARD PLAN RESTRICTED STOCK UNIT AWARD GRANT NOTICE 4D Molecular Therapeutics, Inc., a Delaware corporation, (the “Company”), pursuant to its 2020 Incentive Award Plan, as amended from time to time (the “Plan”), hereby grants to the holder listed below (the “Participant”), an award of restricted stock units (“Restricted Stoc
December 7, 2020	EX-10.4	Form of Indemnification Agreement for directors and officers. EX-10.4 Exhibit 10.4 4D MOLECULAR THERAPEUTICS, INC. INDEMNIFICATION AGREEMENT This Indemnification Agreement (this “Agreement”) is effective as of «Date» by and between 4D Molecular Therapeutics, Inc., a Delaware corporation (the “Company”), and «Indemnitee» (“Indemnitee”). This Agreement supersedes and replaces any and all previous agreements between the Company and the Indemnitee covering indem
December 7, 2020	EX-3.2	Form of Amended and Restated Certificate of Incorporation, to be in effect immediately prior to the consummation of this offering. EX-3.2 Exhibit 3.2 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF 4D MOLECULAR THERAPEUTICS, INC. 4D Molecular Therapeutics, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), certifies that: 1. The name of the Corporation is 4D Molecular Therapeutics, Inc. The Corporation’s original Certificate of Incorporation was filed with the Secretar
December 7, 2020	EX-4.3	Amended and Restated Investors’ Rights Agreement, dated as of April 29, 2020, among the Registrant and the investors party thereto. EX-4.3 Exhibit 4.3 EXECUTION VERSION 4D MOLECULAR THERAPEUTICS, INC. THIRD AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT Table of Contents Page 1. Definitions 2 2. Registration Rights 5 2.1 Demand Registration 5 2.2 Company Registration 7 2.3 Underwriting Requirements 7 2.4 Obligations of the Company 9 2.5 Furnish Information 10 2.6 Expenses of Registration 10 2.7 Delay of Registration 11 2.8 I
November 17, 2020	EX-10.9	Exclusive License and Bailment Agreement, dated December 19, 2013, between the Registrant and The Regents of the University of California. [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10).
November 17, 2020	EX-10.1(A)	2015 Equity Incentive Plan. Exhibit 10.1(a) 4D MOLECULAR THERAPEUTICS, INC. 2015 EQUITY INCENTIVE PLAN Adopted by Board and Stockholders on March 20, 2015, as amended on March 10, 2016, August 27, 2018, September 25, 2019, April 29, 2020 and November 9, 2020 Termination Date: March 20, 2025 1. Purposes of the Plan. The purposes of the Plan are: ? to attract and retain the best available personnel for positions of substantial
November 17, 2020	EX-10.7	Collaboration and License Agreement, dated August 6, 2019, by and between the Registrant and uniQure biopharma B.V. Exhibit 10.7 [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. Execution Copy 8-6-2019 CONFIDENTIAL COLLABORATION AND LICENSE AGREEMENT BY AND BETWEEN 4D MOLECULAR THERAPEUTICS, INC AND UNIQURE BIOPHARMA B.V. August 6, 20
November 17, 2020	EX-10.5	Collaboration and License Agreement, dated November 16, 2017, among the Registrant, F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. Exhibit 10.5 [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. Execution Copy CONFIDENTIAL Collaboration and License Agreement This Agreement is entered into with effect as of the Effective Date (as defined below) by and
November 17, 2020	EX-10.8	Exclusive License and Bailment Agreement, dated December 19, 2013, between the Registrant and The Regents of the University of California. [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10).
November 17, 2020	S-1	Power of Attorney. Table of Contents As filed with the Securities and Exchange Commission on November 17, 2020.
November 17, 2020	EX-10.1(B)	Form of Stock Option Agreement under 2015 Equity Incentive Plan. Exhibit 10.1(b) 4D MOLECULAR THERAPEUTICS, INC. 2015 EQUITY INCENTIVE PLAN STOCK OPTION AGREEMENT This Stock Option Agreement (this ?Agreement?) is made and entered into as of ?DateofGrant? by and between 4D Molecular Therapeutics, Inc., a Delaware corporation (the ?Company?), and ?Participant? (?Participant?). Unless otherwise defined herein, capitalized terms used herein shall have the same defi

FDMT / 4D Molecular Therapeutics, Inc. - تصريحات هيئة الأوراق المالية والبورصات، التقرير السنوي، بيان الوكيل

الإحصائيات الأساسية

SEC Filings

SEC Filings (Chronological Order)